Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai Ruihongdi Pharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for RGL-2102](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20241700 | P1 |
Unknown |
Unknown |
None |